Glucotrack, Inc. (GCTK)
Data as of , from SEC Form 4 filings.
See up to 3 months of GCTK. The 7-day demo opens the 1M and 3M ranges and puts GCTK on your watchlist.
Start 7-day demoLatest GCTK insider trades
Erin Catherine Carter - DirectorGrant or award32 sh- Erin Catherine Carter - DirectorGrant or award1,000 sh
- Erin Catherine Carter
About Glucotrack, Inc. (GCTK)
Glucotrack, Inc. is an SEC registrant, filing under CIK 0001506983, classified as surgical and medical instruments and apparatus. We track it alongside the rest of the Health Care sector. It filed a registration statement with the SEC on 18 September 2026 and has not yet priced an offering.
GCTK Form 4 activity by transaction type, last 90 days
No Form 4 activity for GCTK in the last 90 days.
GCTK insider transactions (Form 4)
134 Form 4 filings on record, the earliest from Mar 25, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Erin Catherine Carter - Director | Grant or award | Common Stock, par value $0.001 per share | 32 | $0.00 | - | |
| Erin Catherine Carter - Director | Grant or award | Common Stock, par value $0.001 per share | 1,000 | $0.00 | - | |
| Erin Catherine Carter - Director | Grant or award | Common Stock, par value $0.001 per share | 386 | $0.00 | - | |
| Erin Catherine Carter - Director | Grant or award | Stock option (right to buy) | 4,055 | $0.00 | - | |
 Luis Malave - Director | Grant or award | Common Stock, par value $0.001 per share | 35 | $0.00 | - | |
| Luis Malave - Director | Grant or award | Common Stock, par value $0.001 per share | 1,200 | $0.00 | - | |
| Luis Malave - Director | Grant or award | Common Stock, par value $0.001 per share | 463 | $0.00 | - | |
| Luis Malave - Director | Grant or award | Stock option (right to buy) | 4,055 | $0.00 | - | |
| Andrew K. Balo - Director | Grant or award | Common Stock, par value $0.001 per share | 75 | $0.00 | - | |
| Andrew K. Balo - Director | Grant or award | Common Stock, par value $0.001 per share | 3,332 | $0.00 | - | |
| Andrew K. Balo - Director | Grant or award | Common Stock, par value $0.001 per share | 1,285 | $0.00 | - | |
| Andrew K. Balo - Director | Grant or award | Stock option (right to buy) | 4,055 | $0.00 | - | |
| Paul Goode - Officer | Other | Common Stock, par value $0.001 per share | 42 | - | - |
GCTK insider trading FAQ
What is the latest insider trade for GCTK?
Glucotrack, Inc. (GCTK) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-10-07. The full record for GCTK runs to 4 Form 4 filings, the earliest from 2025-03-25. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying GCTK stock?
No insider purchases of GCTK were filed in the last 90 days.
How many insiders are selling GCTK stock?
No insider sales of GCTK were filed in the last 90 days.
Where can I see GCTK SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects GCTK Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
4The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Erin Catherine Carter view on EDGAR
- - Luis Malave view on EDGAR
- - Andrew K. Balo view on EDGAR
- - Paul Goode view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where GCTK's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow GCTK with a 7-day demo
- GCTK on your watchlist
- Every GCTK Form 4 filing on record
- Up to 3 months of GCTK price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
